Baseline soluble MICA levels act as a predictive biomarker for the efficacy of regorafenib treatment in colorectal cancer.
Arai J, Otoyama Y, Fujita KI, Goto K, Tojo M, Katagiri A, Nozawa H, Kubota Y, Takahashi T, Ishida H, Tsunoda T, Matsumoto N, Ogawa K, Nakagawa R, Muroyama R, Kato N, Yoshida H.
Arai J, et al. Among authors: takahashi t.
BMC Cancer. 2022 Apr 20;22(1):428. doi: 10.1186/s12885-022-09512-5.
BMC Cancer. 2022.
PMID: 35443621
Free PMC article.